EU/3/03/166

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in June 2019 at the end of the 12-year period of market exclusivity.

On 17 October 2003, orphan designation (EU/3/03/166) was granted by the European Commission to QuadraMed, United Kingdom, for eculizumab for the treatment of paroxysmal nocturnal haemoglobinuria.

The sponsorship was transferred to Alexion Europe SAS, France, in March 2006.

Eculizumab in treatment of paroxysmal nocturnal haemoglobinuria has been authorised in the EU as Soliris since 20 June 2007.

Key facts

Active substance
Eculizumab
Medicine name
Soliris
Disease / condition
Treatment of paroxysmal nocturnal haemoglobinuria
Date of first decision
17/10/2003
Outcome
Expired
EU designation number
EU/3/03/166

Sponsor's contact details

Alexion Europe S.A.S.
1-15, avenue Edouard Belin
92500 Rueil-Malmaison
France
Tel. +33 1 47 10 06 15
E-mail: medicalinformation.europe@alxn.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating